Leadership Changes at Inventiva
Inventiva is pleased to announce a significant leadership transition, marking a pivotal moment for the company. Jason Campagna, MD, PhD, has been appointed as the new President of Research and Development (R&D) and Chief Medical Officer (CMO). He will succeed Pierre Broqua, PhD, and Michael Cooreman, MD. Alongside him, Martine Zimmermann, PharmD, joins as the Executive Vice President of Regulatory Affairs and Quality Assurance, bringing a wealth of experience and expertise.
Jason Campagna’s Vision for R&D
Dr. Campagna joins Inventiva's executive team with a strong background in metabolic disease research, particularly in metabolic dysfunction-associated steatohepatitis (MASH). His prior roles include serving as the CMO at Q32 Bio and leading global programs at Intercept Pharmaceuticals. Throughout his career, he has been deeply involved in the advancement of innovative therapies for liver diseases.
Insights from Dr. Campagna
Expressing his excitement about joining Inventiva, Dr. Campagna stated, "Inventiva has established a robust scientific foundation, and I am eager to lead the charge as we work towards upcoming regulatory submissions for lanifibranor. My experiences have highlighted the urgency and complexity of developing effective MASH therapies, and I believe in the promising results that our ongoing and future studies will show." His vision reflects a deep commitment to addressing the needs of patients suffering from MASH.
Martine Zimmermann’s Regulatory Expertise
Joining Dr. Campagna, Dr. Martine Zimmermann is well-prepared to take on her new role as EVP of Regulatory Affairs and Quality Assurance. Previously, she served as Senior Vice President at Ipsen, where she successfully led teams to secure regulatory approvals for critical liver disease medications. Her role will be instrumental as the company navigates the regulatory landscape moving forward.
Dr. Zimmermann’s Experience
Dr. Zimmermann conveyed her enthusiasm about her new leadership position by stating, "Entering this critical regulatory phase for lanifibranor is an exciting challenge. My extensive experience with global regulatory strategies will be vital in guiding our approach towards securing any necessary approvals for innovative therapies at Inventiva." Her skill set perfectly complements the company’s objectives, particularly in light of the anticipated launch of their Phase 3 clinical trial.
Future Directions for Inventiva
With the appointments of Dr. Campagna and Dr. Zimmermann, Inventiva underscores its commitment to sustainable growth and operational excellence. The imminent readout of the NATiV3 Phase 3 study marks a critical milestone in the development of lanifibranor, a first-in-class pan-PPAR agonist, which is currently under evaluation for treating MASH.
CEO’s Perspective
Frederic Cren, Inventiva’s CEO, expressed confidence in the leadership transition. He remarked, "Jason and Martine bring invaluable expertise during this pivotal time as we prepare for the NATiV3 Phase 3 trial’s results, setting the stage for potential future approvals and commercialization of lanifibranor. Their leadership is crucial as we strive to meet our goals for addressing unmet medical needs in this field." This statement emphasizes the company’s robust strategy for addressing chronic liver diseases.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company dedicated to developing innovative oral therapies for patients with MASH and other conditions that currently have significant unmet medical needs. The company’s focus centers on lanifibranor, designed to treat chronic liver diseases that affect countless individuals globally.
Company Background and Stock Information
Listed on Euronext Paris as well as the Nasdaq Global Market under the ticker IVA, Inventiva is committed to advancing its innovative therapies and maximizing their potential impact on public health. Investors and stakeholders can track the company’s progress and developments through its official platforms.
Frequently Asked Questions
What are the key leadership changes at Inventiva?
Jason Campagna has been appointed as the President of R&D and CMO, while Martine Zimmermann takes on the role of EVP of Regulatory Affairs and Quality Assurance.
What is the significance of these appointments?
These leadership transitions are crucial as Inventiva prepares for critical regulatory developments and the advancement of its clinical trials, particularly concerning lanifibranor.
What experience does Jason Campagna bring to Inventiva?
Dr. Campagna has extensive experience in the MASH field, having held leadership roles in significant related projects and clinical programs.
How will Martine Zimmermann contribute to the company?
Dr. Zimmermann’s expertise in regulatory affairs will be essential in guiding the company’s regulatory strategy for lanifibranor, particularly as it approaches pivotal approvals.
What future developments can we expect from Inventiva?
The company is currently focused on the upcoming readout of the NATiV3 Phase 3 study and advancing lanifibranor through the regulatory approvals process.
